Loss of Smell, Taste Less Likely With Newer COVID-19 Variants
Lower risk for developing chemosensory loss observed with alpha, delta, and omicron variants
Lower risk for developing chemosensory loss observed with alpha, delta, and omicron variants
The totality of the evidence led the FDA to determine that the criteria for issuing an EUA had not been met.
Findings seen in immunosuppressed patients with rheumatic and musculoskeletal diseases, solid organ transplant recipients
Persistent viral shedding associated with in-hospital delirium and increased six-month mortality
Reduction in viral load from baseline greater with lenacapavir versus placebo among those with multidrug-resistant HIV-1 infection
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
Reports of symptoms returning in patients several days after completing the five-day regimen of Paxlovid
The phase 1 trial is expected to last four years and enroll 40 participants
Series of case reports shows some success with Paxlovid in treating patients with long COVID
However, the CDC notes that the risk to the general public is still low